ASCL2 and gastric cancer: It was able to downregulate the expression level of miR223, contribute to EMT (the epithelial-mesenchymal transition), and promote gastric tumor metastasis, which indicated that ASCL2 might serve as a therapeutic target in the treatment of GC [44].